Kyle LaHucik

Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so far this year.

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for biotech IPOs since 2022.

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said Monday morning. The biotech plans to report results ...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with the Murdoch Children's Research Institute in Australia. The California biotech, which has ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the exclusive ex-China license to the biotech's PD-1xVEGF bispecific.

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it unveiled with a $400 million-plus fund ...

Eli Lilly is deepening its presence in the non-opioid pain field by buying California biotech SiteOne Therapeutics, which is in a similar arena as the recent landmark approval for Vertex's pain drug.

One of the nation’s premier cancer institutions is looking at a hefty second batch of capital to support future drugs in the field.

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement disorder known as dystonia.